| Not Yet Recruiting | FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple NCT07221032 | Medical College of Wisconsin | Phase 1 |
| Not Yet Recruiting | DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM NCT07377435 | David Avigan | Phase 1 |
| Not Yet Recruiting | Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory NCT07479979 | Natalie Callander | Phase 1 / Phase 2 |
| Recruiting | Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleuce NCT07093554 | Medical College of Wisconsin | Phase 1 |
| Recruiting | Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma NCT07359014 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Withdrawn | Melflufen for Elderly Patients With Relapsed Myeloma NCT06682637 | Fondazione EMN Italy Onlus | Phase 2 |
| Recruiting | A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elra NCT06799026 | David Avigan | Phase 1 |
| Recruiting | Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone NCT06561854 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Recruiting | MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM NCT06171685 | Multiple Myeloma Research Consortium | Phase 2 |
| Recruiting | Elranatamab in R/R Multiple Myeloma NCT06138275 | Massachusetts General Hospital | Phase 2 |
| Recruiting | Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma NCT05789303 | University of Chicago | Phase 2 |
| Active Not Recruiting | A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Ce NCT05742217 | Pfizer | — |
| Terminated | Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor NCT05117008 | Medical College of Wisconsin | Phase 2 |
| Unknown | A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma NCT05430945 | Zhejiang University | EARLY_Phase 1 |
| Active Not Recruiting | A Study of MCARH109 and MCARH125 in People With Multiple Myeloma NCT05431608 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Terminated | Descartes-25 in Relapsed/Refractory Multiple Myeloma NCT05113342 | Cartesian Therapeutics | Phase 1 |
| Active Not Recruiting | A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma NCT04302324 | Weill Medical College of Cornell University | Phase 2 |
| Recruiting | Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With M NCT05243212 | Sheba Medical Center | Phase 1 / Phase 2 |
| Unknown | B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma NCT05150522 | Shenzhen University General Hospital | Phase 1 / Phase 2 |
| Withdrawn | INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma NCT04355039 | Medical College of Wisconsin | Phase 1 |
| Withdrawn | A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Mye NCT04918511 | Oncopeptides AB | Phase 1 |
| Not Yet Recruiting | A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma NCT04670055 | Zhejiang University | EARLY_Phase 1 |
| Not Yet Recruiting | A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy NCT04541368 | Zhejiang University | EARLY_Phase 1 |
| Unknown | Multiple Myeloma Turkish Prospective Patient Registry NCT04143932 | Turkish Hematology Association | — |
| Unknown | Carfilzomib in Combination for the Treatment of RR MM NCT04004338 | Black Sea Hematology Association | — |
| Unknown | Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refract NCT03143049 | National University Hospital, Singapore | Phase 3 |
| Completed | Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib NCT01775553 | Ajai Chari | Phase 2 |